New York City Metropolitan Area
Rare Disease Commercialization | Specialty Oncology | Global Launch Excellence | Scientific Marketing | New Product Planning | AI-Enabled Strategy Global Biopharma Leader Bridging Medical Science & Commercial Strategy I am a strategic and globally experienced commercial leader in the biopharmaceutical industry, bringing a unique blend of marketing, medical strategy, and scientific communications expertise. Recognized for driving the successful commercialization of rare disease, oncology, and specialty medicine portfolios through insight-driven, cross-functional leadership. Proven ability to scale teams, build launch readiness, and integrate AI/ML innovation into patient identification and engagement strategies. 🚀 Proven Success in Rare & Specialty Launches I have led blockbuster product launches and revitalized portfolios across rare disease, specialty oncology, respiratory, type 2 diabetes, women’s health, and biosimilars. By integrating AI/ML-powered patient identification strategies, I have driven significant improvements in patient finding, diagnosis, and engagement, turning untapped opportunities into real-world impact. 🤝 Collaborative Leadership, Team Building & Growth A passionate people leader, I have successfully built and scaled high-performing marketing, medical, and commercial teams—promoting over 10 team members into leadership roles. I thrive on cross-functional collaboration, aligning stakeholders across global markets to execute complex initiatives in value-based care, disease education, and health equity. 🌍 Future-Focused & Board-Ready As I continue advancing innovation in healthcare, I am actively seeking Board of Director opportunities to contribute my expertise in commercial strategy, scientific marketing, and global market development. I’m excited to collaborate with forward-thinking leaders to shape the future of biopharma and deliver lasting impact for patients and communities worldwide. 🔗 Let’s connect to explore how we can drive transformational growth together. 📧 [email protected]
Commercial Strategy | Launch Excellence | Rare Disease & Oncology | AI/ML Market Analytics Accomplishments: Architecting end-to-end commercialization strategies for stealth-stage rare disease, oncology, and immunology assets — spanning TPP development, launch readiness, and cross-functional alignment across clinical, regulatory, and commercial teams. Applied AI/ML-powered epidemiology and claims analytics to sharpen patient identification and market-sizing; secured seed funding for a rare oncology asset through investor-ready go-to-market strategy and VC/CVC co-development partnership. 𝗦𝗸𝗶𝗹𝗹𝘀: Go-to-Market Planning · Cross-functional Leadership · Investor Strategy · Early-Stage Biotech · Pipeline Commercialization
Rare Disease Commercialization | Oncology | Brand Strategy | Team Building Accomplishments: Executive Director. Leading KKNA's rare disease marketing function across North America focused on developing and launching innovative monoclonal antibody product (rare genetic disorders, rare endocrine tumors), go-to market, commercial strategies with communities’ needs and stakeholder expectations.
Accomplishments: • Attending Networking Events • Researching Industry Leaders • Tracking Industry Trends • Participating in Industry Discussions
Rare Disease Commercialization | Portfolio Strategy | New Product Planning Accomplishments: Expanded Vertex’s Cystic Fibrosis (CF) program, portfolio and medical alliances by driving partner enablement, introduction of a new scientific platform, and new product scientific marketing of novel therapies. • Led a team of 6 direct reports for portfolio & communications strategy for the entire Vertex Cystic Fibrosis portfolio. •Spearheaded key aspects of record-setting US launch for Trikafta, ranking as the single most valuable late-stage therapy in the global pipeline according to Vantage/Evaluate. Platinum Vertex Outstanding Contribution Award Program nomination. •Trikafta was 1 of 4 People’s Choice Breakthrough of the Year finalists for Science Magazine, and was selected by USA Today as 1 of 15 best health news stories over the past decade, further increasing brand awareness for this CF therapy.
Oncology product launch & scientific marketing; key liaison bridging communications between U.S. cross-functional oncology teams and executive leadership prioritizing solid tumor assets and brand strategy. Accomplishments: • Partnered with the US Franchise Lead to drive top-level strategic direction with tactical execution, led team to steer planning, integration and support for evidence generation activities spanning the multi-billion-dollar solid tumor portfolio. • Established a strategically-aligned integrated evidence generation plan & scientific communications platform which improved collaboration with cross-functional partners.